Program

Keynote Session

Chairpersons: David P. Carbone, Vanderbilt-Ingram Cancer Center, Nashville, TN, and Roy S. Herbst, UT M. D. Anderson Cancer Center, Houston, TX
6:00 p.m.-7:30 p.m.

Studying tumor evolution in mouse models of lung cancer
Tyler Jacks, David H. Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, MA

Welcome Reception

7:30 p.m.-8:30 p.m.

Plenary Session 1: Tyrosine Kinase Signaling and Targeted Therapy

Chairpersons: Matthew L. Meyerson, Dana-Farber Cancer Institute, Boston, MA, and William Pao, Vanderbilt University, Nashville, TN
8:00 a.m.-10:00 a.m.

Introduction
Matthew L. Meyerson

Discovery and clinical application of a novel oncogene, EML4-ALK, in lung cancer
Hiroyuki Mano, Jichi Medical University, Tochigi, Japan

Overcoming acquired resistance to EGFR inhibitors
Jeffrey Engelman, Massachusetts General Hospital, Charlestown, MA

Targeting the insulin and insulin-like growth factor receptors: Efficacy and biology
Michael Pollak, McGill University, Montreal, QC, Canada 

*Activation of c-Met by EGFR modulates invasive phenotypes in NSCLC
Austin M. Dulak, University of Pittsburgh, Pittsburgh, PA

Plenary Session 2: Early Detection for Premalignant Lesions and Field Cancerization

Chairpersons: Denise R. Aberle, UCLA David Geffen School of Medicine, Los Angeles, CA, and Elisabeth M.P. Brambilla, Hôpital A. Michallon, Grenoble, France 
10:30 a.m.-12:30 p.m.

NLST update and biospecimen opportunity
Denise R. Aberle

Airway gene expression as a biomarker for lung cancer
Avrum E. Spira, Boston University Medical Center, Boston, MA

Histone modification as an early mark of epigenetic change
Elisabeth M.P. Brambilla 

*Sniffing NSCLC and SCLC using nanoparticle based artificial olfactory system NanoNose
Nir Peled, University of Colorado Cancer Center, Aurora, CO

*Blood-based biomarker profiles for detecting lung cancer
Gina Lee, David Geffen School of Medicine at UCLA, Los Angeles, CA

Poster Session A

12:30 p.m.-2:30 p.m.

Concurrent Sessions I

2:30 p.m.-4:30 p.m.

• Detection and Prevention: From Mouse to Man

  Chairpersons: Steven M. Dubinett, UCLA David Geffen School of Medicine, Los Angeles, CA, and Jonathan M. Kurie, UT M. D. Anderson Cancer Center, Houston, TX

  Personalized, targeted chemoprevention for lung cancer: Is it possible?
  Steven M. Dubinett

  Moving prognostic epigenetic markers for lung cancer into the clinic
  Malcolm V. Brock, Johns Hopkins University, Baltimore, MD

  Preclinical lung cancer chemoprevention models
  Robert L. Keith, University of Colorado Health Sciences Center, Denver, CO

  Novel targets in metastasis prevention
  Jonathan M. Kurie

• Other Thoracic Cancers (Mesothelioma, Thymic, Neuroendocrine)

  Chairpersons: Pierre P. Massion, Vanderbilt-Ingram Cancer Center, Nashville, TN, and Valerie W. Rusch, Memorial Sloan-Kettering Cancer Center, New York, NY
  
  Copy number alterations in the pathogenesis of small cell lung cancer
  Pierre P. Massion
  
  Personalizing novel mesothelioma treatments for conventional and novel therapies
  Steven M. Albelda, University of Pennsylvania, Philadelphia, PA 
   
  Current insights into thymoma and thymic carcinoma
  Valerie W. Rusch 

  *Mouse models to study roles of TSG and signaling pathway in SCLC development
  Kwon-Sik Park, Stanford University, Stanford, CA

  *Matching phenotype-genotype interactions identifies mTOR as a druggable molecule in Malignant Pleural Mesothelioma targeted therapeutic approach
  Giulia M. Stella, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

• JAK/STAT Pathways as Therapeutic Targets

  Chairpersons: Eric B. Haura, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, and Tetsuya Mitsudomi, Aichi Cancer Center Research Institute, Nagoya, Japan

  Targeting JAK/STAT signaling for cancer therapy
  Richard Jove, City of Hope, Duarte, CA

  Targeting EGFR, Src, and Stat3 pathway for cancer therapy
  James Turkson, University of Central Florida, Orlando, FL

  Targeting STATs for the molecular therapy of lung cancer: Translation from the lab to the clinic
  David A. Frank, Dana-Farber Cancer Institute, Boston, MA
  
  JAK activation as a mechanism for resistance to c-Src inhibition in NSCLC
  Faye M. Johnson, UT M. D. Anderson Cancer Center, Houston, TX

Advocacy, Regulatory, and Funding Issues

Chairpersons: Kim Norris, Lung Cancer Foundation of America, Palos Verdes Estates, CA, and Debra A. Violette, Dana-Farber Lung SPORE, Lung Cancer Alliance, Augusta, ME
4:30 p.m.-6:00 p.m.

Special Address
Lori Monroe, Lung Cancer Foundation of America, Bowling Green, KY

Panel Discussion

Plenary Session 3: Cancer Stem Cells

Chairpersons: Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD, and John D. Minna, UT Southwestern Medical Center, Dallas, TX
8:00 a.m.-10:00 a.m.

Lung cancer stem cells: Identification and translation to the clinic
John D. Minna

Epigenetic therapy, cancer self-renewing cells, and lung cancer
Stephen B. Baylin

Lung cancer stem cells and the cytokine network
Vera Levina, University of Pittsburgh Cancer Institute, Pittsburgh, PA

*Targeting Rac1 GTPase benefits both human lung adenocarcinoma stem cell and non-stem cell therapies
Shailaja Akunuru, Children's Hospital Research Foundation, University of Cincinnati, Cincinnati, OH

Plenary Session 4: Genome-Wide Approaches to Risk

Chairpersons: Bruce A. J. Ponder, CRUK, Cambridge Research Institute, Cambridge, United Kingdom, and Margaret R. Spitz, UT M. D. Anderson Cancer Center, Houston, TX
10:30 a.m.-12:30 p.m.

Genome-wide approaches to risk: Lessons from breast and prostate
Bruce A. J. Ponder

Convergence of genetic findings for nicotine dependence and lung cancer 
Laura J. Bierut, Washington University School of Medicine, St. Louis, MO

COPDGene: Risk factors for COPD and lung cancer
James D. Crapo, University of Colorado Health Sciences Center, Denver, CO

Identifying causal factors for lung cancer by genome-wide studies
Christopher I. Amos, UT M.D. Anderson Cancer Center, Houston, TX

Concurrent Sessions II

2:30 p.m.-4:30 p.m.

• Lung Cancer Profiling with microRNAs

  Chairpersons: Glen J. Weiss, Translational Genomics Research Institute, Phoenix, AZ, and Ignacio I. Wistuba, UT M. D. Anderson Cancer Center, Houston, TX

  Application of miRNAs in the treatment of lung cancer
  Glen J. Weiss
  
  MicroRNA alterations in the pathogenesis of lung cancers
  Takashi Takahashi, Nagoya University, Nagoya, Japan
  
  MicroRNA binding site SNPs and lung cancer risk
  Joanne B. Weidhaas, Yale University, New Haven, CT

  *The role of micro RNA 125a-3P in the pathogenesis of lung cancer
  Saswati Hazra, Geffen School of Medicine at UCLA, Los Angeles, CA

  
  *MicroRNA affinity assay
  Simon Spivack, Albert Einstein College of Medicine, Bronx, NY

• Mouse Models of Lung Cancer

  Chairperson: Kwok-kin Wong, Dana-Farber Cancer Institute, Boston, MA

  The use of genetically engineered mouse lung cancer models for preclinical testing of novel therapeutics
  Kwok-kin Wong
  
  The multiple roles of Kras in mouse epithelial cancer development
  Minh D. To, UCSF Comprehensive Cancer Center, San Francisco, CA
  
  Preclinical evaluation of genetically engineered mouse models of NSCLC and SCLC
  Leisa Johnson, Genentech, Inc., South San Francisco, CA

  *BRAF deletion and pharmacologic inhibition enhance KRAS driven tumorigenesis
  Christopher L. Murriel, Genentech, Inc., South San Francisco, CA

  
  *Novel lung cancer model mediated by lentiviral gene delivery
  Yifeng Xia, Salk Institute for Biological Studies, La Jolla, CA 

• Other Biomarkers

  Chairpersons: David P. Carbone, Vanderbilt-Ingram Cancer Center, Nashville, TN, and Fred R. Hirsch, University of Colorado Cancer Center, Aurora, CO

  Proteomics-based biomarker development in NSCLC
  David P. Carbone

  Gene copy number for EGFR and IGF-1R: Clinical implications
  Fred R. Hirsch

  Prognostic and predictive biomarkers for adjuvant chemotherapy
  Ming Sound Tsao, University of Toronto, Toronto, ON, Canada

  *High throughput protein biomarker discovery and translation into clinical diagnostics for oncology using the SomaLogic SOMAmer-based assay
  Rachel Ostroff, SomaLogic, Inc., Boulder, CO

  
  *Gene expression changes in the bronchial airway epithelium of smokers with lung cancer may reflect common pathways of tobacco-related carcinogenesis
  Adam C. Gower, Boston University, Boston, MA

Poster Session B

4:30 p.m.-6:30 p.m.

Plenary Session 5: Angiogenesis and the Tumor Microenvironment

Chairpersons: Roy S. Herbst, UT M. D. Anderson Cancer Center, Houston, TX, and Joan H. Schiller, UT Southwestern Medical Center, Dallas, TX
8:00 a.m.-10:00 a.m.

Antiangiogenic agents in the clinic: Are we there yet?
Joan H. Schiller

Molecular signature for Bevacizumab in E4599
Heinz-Josef Lenz, USC/Norris Comprehensive Cancer Center, Los Angeles, CA

Contrasting effects of different antiangiogenic drugs (TKIs and antibodies) on early vs. late stage metastatic disease
Robert S. Kerbel, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

*Identification of tumor cell-derived factors associated with resistance to anti-VEGF therapy in non-small cell lung cancer
Laura A. Sullivan, University of Texas Southwestern Medical Center, Dallas, TX

*Phase II studies of ASA404 (vadimezan, DMXAA) plus carboplatin and paclitaxel in advanced squamous and non-squamous non-small cell lung cancer: blood and lymphatic adverse events
M. J. McKeage, University of Auckland, Auckland, New Zealand

Additional proffered talk to be announced

Plenary Session 6: Drug Design and New Targets

Chairpersons: David R. Gandara, UC Davis Cancer Center, Sacramento, CA, and Nagahiro Saijo, Kinki University School of Medicine, Osaka-Sayama, Japan
10:30 a.m.-12:30 p.m.

Personalized therapeutic approaches for advanced NSCLC: The MDACC BATTLE program
Roy S. Herbst, UT M. D. Anderson Cancer Center, Houston, TX

Personalizing chemotherapy for advanced NSCLC
David R. Gandara

New targets for chemoprevention and therapy for lung cancer
Scott M. Lippman, UT M. D. Anderson Cancer Center, Houston, TX

New target discovery: A drug company perspective
Mace L. Rothenberg, Pfizer, Inc., San Diego, CA

DEPARTURE